Idunox

Idunox is a Swiss preventive health technology startup and CSEM spin-off developing products to identify long-term disease risks and support earlier, more personalized prevention. Its platform combines routine blood biomarkers, multi-omics data, lifestyle information, and health history to estimate future wellbeing and disease risk, explain the markers influencing results, and set individualized biomarker target ranges.

The company’s products include IduScore, which estimates 10-year wellbeing and disease risks; IduOmics, which uses multi-omic markers and health data to assess risks across chronic diseases; and IduRange, which defines personalized optimal ranges for biomarkers. The platform also provides tailored preventive recommendations, including lifestyle and, where relevant, diagnostic or therapeutic actions, prioritized by expected impact. Idunox’s current disease focus includes cardiovascular disease, chronic kidney disease, Alzheimer’s, and lung cancer. Its models were developed and validated using longitudinal UK Biobank data, and the company reports benchmarking against established clinical risk methods. IduScore is planned to launch in Switzerland in August 2026 through an at-home testing partner.